Antibacterial resistance leadership group: open for business

Abstract

Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.

Keywords: ARLG; Leadership Group; antibacterial resistance; clinical research; clinical trials.

Figure 1.

Antibacterial Resistance Leadership Group organizational structure. Abbreviations: ARLG, Antibacterial Resistance Leadership Group; CTU, Clinical Trials Unit; ESI, early-stage investigator; LC, Laboratory Center; LOC, Leadership and Operations Center; NIAID, National Institute of Allergy and Infectious Diseases; PK, Pharmacokinetics; SDMC, Statistics and Data Management Center; SEP, Special Emphasis Panels; TBD, to be determined; VTEUs, Vaccine and Treatment Evaluation Units.